Kenneth Pienta
Kenneth Pienta
Professor of Urology and Oncology, Johns Hopkins University
Dirección de correo verificada de jhmi.edu - Página principal
TítuloCitado porAño
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins, DR Rhodes, S Perner, SM Dhanasekaran, R Mehra, XW Sun, ...
science 310 (5748), 644-648, 2005
37252005
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally, SM Dhanasekaran, M Zhou, TR Barrette, C Kumar-Sinha, ...
Nature 419 (6907), 624, 2002
25172002
Delineation of prognostic biomarkers in prostate cancer
SM Dhanasekaran, TR Barrette, D Ghosh, R Shah, S Varambally, ...
Nature 412 (6849), 822, 2001
19172001
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
JS De Bono, HI Scher, RB Montgomery, C Parker, MC Miller, H Tissing, ...
Clinical cancer research 14 (19), 6302-6309, 2008
17932008
The mutational landscape of lethal castration-resistant prostate cancer
CS Grasso, YM Wu, DR Robinson, X Cao, SM Dhanasekaran, AP Khan, ...
Nature 487 (7406), 239, 2012
15572012
Integrative clinical genomics of advanced prostate cancer
D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ...
Cell 161 (5), 1215-1228, 2015
15322015
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone
RS Taichman, C Cooper, ET Keller, KJ Pienta, NS Taichman, ...
Cancer research 62 (6), 1832-1837, 2002
11222002
Integrative molecular concept modeling of prostate cancer progression
SA Tomlins, R Mehra, DR Rhodes, X Cao, L Wang, SM Dhanasekaran, ...
Nature genetics 39 (1), 41, 2007
8882007
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
SA Tomlins, B Laxman, SM Dhanasekaran, BE Helgeson, X Cao, ...
Nature 448 (7153), 595, 2007
8222007
α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
MA Rubin, M Zhou, SM Dhanasekaran, S Varambally, TR Barrette, ...
Jama 287 (13), 1662-1670, 2002
7852002
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
S Varambally, J Yu, B Laxman, DR Rhodes, R Mehra, SA Tomlins, ...
Cancer cell 8 (5), 393-406, 2005
7132005
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
DR Robinson, YM Wu, P Vats, F Su, RJ Lonigro, X Cao, ...
Nature genetics 45 (12), 1446, 2013
6852013
Autoantibody signatures in prostate cancer
X Wang, J Yu, A Sreekumar, S Varambally, R Shen, D Giacherio, R Mehra, ...
New England Journal of Medicine 353 (12), 1224-1235, 2005
6652005
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
S Shangary, D Qin, D McEachern, M Liu, RS Miller, S Qiu, ...
Proceedings of the National Academy of Sciences 105 (10), 3933-3938, 2008
6632008
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
X Sun, G Cheng, M Hao, J Zheng, X Zhou, J Zhang, RS Taichman, ...
Cancer and Metastasis Reviews 29 (4), 709-722, 2010
6222010
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
RB Shah, R Mehra, AM Chinnaiyan, R Shen, D Ghosh, M Zhou, ...
Cancer research 64 (24), 9209-9216, 2004
6062004
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
Q Wang, W Li, XS Liu, JS Carroll, OA Jänne, EK Keeton, AM Chinnaiyan, ...
Molecular cell 27 (3), 380-392, 2007
5892007
TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
S Perner, F Demichelis, R Beroukhim, FH Schmidt, JM Mosquera, S Setlur, ...
Cancer research 66 (17), 8337-8341, 2006
5722006
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
PEG Esper, FEI Mo, G Chodak, M Sinner, D Cella, KJ Pienta
Urology 50 (6), 920-928, 1997
5701997
Risk factors for prostate cancer
KJ Pienta, PS Esper
Annals of internal medicine 118 (10), 793-803, 1993
5661993
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20